ADA 2026 GLP-1 Recap: Survodutide, Retatrutide, MASH, and the Pipeline Shift

The American Diabetes Association 86th Scientific Sessions wrapped up June 10, 2026, in New Orleans. This was the most consequential ADA meeting for GLP-1 drugs in years. Full Phase 3 data for the two most-watched pipeline drugs debuted. A new class of liver disease data emerged. And the message was clear: the GLP-1 drug class is moving beyond weight loss.

Here is what happened, what it means, and what to watch next.

Helpful Products for GLP-1 Users

If you are on a GLP-1 medication or preparing to start, these help:

Ginger chews — Nausea relief during dose escalation. Ginger chews are portable and effective.
Electrolyte packets — Dehydration worsens side effects. LMNT packets are zero sugar.
Protein powder — Appetite drops fast on GLP-1s. A whey protein powder helps you hit daily protein goals.
Smart scale — Track body composition changes. A smart body scale syncs to your phone.

GLPSpot may earn from qualifying purchases.

1. Retatrutide: Full TRIUMPH-1 Data Delivers

Eli Lilly presented the complete TRIUMPH-1 dataset — the Phase 3 general obesity trial that reported top-line results on May 21, 2026. This was the first time the full data was available to the medical community, and the numbers held up under scrutiny.

Key TRIUMPH-1 results at 80 weeks

Dose	Weight Loss	Lbs Lost	≥30% Weight Loss	Waist Reduction
Retatrutide 4 mg	−19.0%	47.2 lbs	15.3%	−6.4 in
Retatrutide 9 mg	−25.9%	64.4 lbs	37.9%	−8.6 in
Retatrutide 12 mg	−28.3%	70.3 lbs	45.3%	−9.5 in
Placebo	−2.2%	5.5 lbs	0.5%	−1.4 in

The extension data was even more notable: participants with BMI ≥35 who continued to 104 weeks reached 30.3% average weight loss (85 lbs) at the 12 mg dose — the highest average weight loss reported in any Phase 3 obesity trial to date.

New details from the full presentation

The ADA presentation revealed more than the press release:

65.3% of participants on 12 mg dropped below BMI 30 — including 37.5% of those who started with class 3 obesity (BMI ≥40)
Cardiometabolic improvements across all doses: reductions in non-HDL cholesterol, triglycerides, systolic blood pressure, and hsCRP (inflammation marker)
Dysesthesia (tingling/burning sensation) affected 20.9% at 12 mg — mostly mild, but a signal to watch
At the 4 mg dose, discontinuation due to side effects was 3.0% — lower than placebo (4.9%), an unusual finding suggesting the lowest dose may have a favorable tolerability profile

What it means

Retatrutide's weight loss numbers now exceed every approved GLP-1 drug. But cross-trial comparisons are not head-to-head studies. The real question is whether retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) translates to meaningfully better outcomes in practice — and that requires FDA approval, which is still months away at minimum.

For the full breakdown, see our Retatrutide Guide.

2. Survodutide: Phase 3 Data Published in Nature Medicine

Boehringer Ingelheim presented results from two Phase 3 SYNCHRONIZE trials, simultaneously published in Nature Medicine on June 7, 2026.

SYNCHRONIZE-1 (obesity)

Met co-primary endpoints in adults with obesity or overweight without type 2 diabetes. Achieved sustained weight loss at the highest dose. Specific percentage data is pending full publication, but the results confirmed Phase 2 findings of up to ~19% weight loss.

SYNCHRONIZE-MASLD (liver disease)

This is the breakthrough result:

34% visceral fat reduction — the metabolically harmful fat around internal organs
63% liver fat reduction — directly relevant for fatty liver disease (MASLD/MASH)
Minimized lean mass loss — a differentiator vs other GLP-1s that can cause significant muscle loss

This is the first GLP-1-class drug to show such strong MASH/MASLD data in Phase 3. The liver disease angle is significant because MASLD affects an estimated 30% of US adults and has very few effective treatments.

Why the liver data matters

Survodutide is a dual GLP-1/glucagon agonist. The glucagon mechanism appears to target liver fat directly — something GLP-1-only and GLP-1/GIP drugs do not do as effectively. If approved, survodutide could be the first GLP-1-based treatment specifically for fatty liver disease.

For the full analysis, see our Survodutide Guide.

3. Beyond Weight Loss: The New Frontier

The clearest theme at ADA 2026 was that GLP-1 drugs are being studied — and positioned — as treatments for conditions beyond obesity.

Sleep apnea

Zepbound (tirzepatide) is already FDA-approved for obstructive sleep apnea (OSA). New data presented at ADA reinforced the connection between GLP-1-mediated weight loss and OSA improvement. Retatrutide's Phase 3 program also includes a sleep apnea trial, with results expected later in 2026.

See our GLP-1 and Sleep Apnea Guide for current knowledge.

Cardiovascular outcomes

Semaglutide's SELECT trial established cardiovascular benefit for Wegovy. At ADA 2026, researchers discussed ongoing cardiovascular outcomes trials for retatrutide and tirzepatide, with results expected in 2026-2027. A Mounjaro MACE (Major Adverse Cardiovascular Events) decision is expected mid-2026.

Liver disease (MASLD/MASH)

Survodutide's data was the headline, but it was not the only liver story. Semaglutide also shows promise for MASH resolution. The field is moving toward GLP-1-based drugs becoming a standard treatment for fatty liver disease — a condition that affects millions and has had virtually no effective pharmacotherapy.

See our GLP-1 and Liver Health Guide for the current picture (note: this article was last updated April 4 and does not yet include the ADA 2026 data).

Kidney disease

The FLOW trial for semaglutide in diabetic kidney disease was discussed. GLP-1 drugs are increasingly being recognized for kidney-protective effects beyond blood sugar control.

See our GLP-1 and Kidney Health Guide for more.

4. The Pipeline at ADA: Where Things Stand

Drug	Company	Mechanism	Phase	Key ADA Data	Earliest Approval
Retatrutide	Eli Lilly	GLP-1 + GIP + glucagon	Phase 3	TRIUMPH-1: 28.3% at 80 wks	2027
Survodutide	Boehringer Ingelheim	GLP-1 + glucagon	Phase 3	SYNCHRONIZE: 63% liver fat reduction	2027-2028
CagriSema	Novo Nordisk	GLP-1 + amylin	FDA review	No new data; decision late 2026/early 2027	Late 2026 / 2027
VK2735	Viking Therapeutics	GLP-1 + GIP	Phase 2	ECO 2026 oral data (12.2% in 13 wks); not at ADA	2028-2029
Amycretin	Novo Nordisk	GLP-1 + amylin (pill)	Phase 2	No new data at ADA	2029-2030

CagriSema was discussed in pipeline sessions but had no new data. The FDA decision is the next catalyst.

5. What Approved Drugs Gained at ADA

The pipeline drugs dominated headlines, but there were updates for currently available medications too:

Wegovy HD (7.2 mg) — Real-world data continues to accumulate for patients who plateaued on standard 2.4 mg. See our Wegovy HD Guide.
Foundayo (orforglipron) — Early real-world prescribing data presented. The GLP-1 pill launched in May 2026 and insurance coverage is expanding. See our Foundayo Guide.
Ozempic oral tablets — Post-launch data on the 3 mg, 7 mg, and 14 mg tablets confirmed cardiovascular risk reduction from the peptide oral formulation. See our Semaglutide News.
Mounjaro/Zepbound — Awaiting MACE cardiovascular indication decision, expected mid-2026. This would be a competitive milestone against Ozempic.

What to Watch Next

CagriSema FDA decision — Expected late 2026 or early 2027. This is the next approval event.
Retatrutide remaining Phase 3 trials — Sleep apnea, cardiovascular outcomes, and liver disease results expected throughout 2026.
Mounjaro MACE decision — Expected mid-2026. If approved, it changes the competitive landscape.
Survodutide full obesity data — The specific weight loss percentage from SYNCHRONIZE-1 is pending full publication.
Zepbound pill (oral tirzepatide) — Phase 3 continues. An effective oral tirzepatide would be a major advance.

The Bottom Line

ADA 2026 confirmed that the GLP-1 space is entering a new phase. The drugs are getting stronger (retatrutide's 28.3%), the targets are expanding (survodutide's liver data), and the class is being repositioned from weight loss injections to metabolic disease treatments.

But none of the pipeline drugs are available today. The five FDA-approved GLP-1 medications — Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo — remain the only options patients can actually get. Start with what works now. You can always switch later if a new drug proves better for you.

The pace of innovation is real. The hype is also real. The gap between them is measured in years of clinical trials and FDA review.

This article is for informational purposes only and does not constitute medical advice. Drugs described as "in trials" or "under review" are not FDA-approved unless explicitly stated. Always talk to your healthcare provider before starting, stopping, or changing any medication.